Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone Propionate and Salmeterol from Different Inhalers
NCT02215122Phase 1Completed
- Sponsor
- Mylan
- Start
- Oct 2013
- Primary completion
- Nov 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate nasal spray and salmeterol in asthma and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Mylan. Primary endpoints: Area Under the Curve at 3 days and Maximum Plasma Concentration at 3 days. Started Oct 2013; status: completed.
02
Drugs
fluticasone propionate nasal spraysalmeterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02215122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215122.